Elanco Animal Health Incorporated Common Stock (ELAN)
18.35
+0.00 (0.00%)
NYSE · Last Trade: Sep 2nd, 8:00 AM EDT
Detailed Quote
Previous Close
18.35
Open
-
Bid
18.18
Ask
18.30
Day's Range
N/A - N/A
52 Week Range
8.020 - 18.87
Volume
261
Market Cap
9.07B
PE Ratio (TTM)
21.34
EPS (TTM)
0.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
11,024,897
Chart
About Elanco Animal Health Incorporated Common Stock (ELAN)
Elanco Animal Health Inc is a global leader in the development and manufacturing of products for animal health and well-being. The company focuses on providing innovative solutions for companion and livestock animals, which include a wide range of vaccines, pharmaceuticals, and nutritional products designed to prevent and treat diseases. By combining science and technology, Elanco aims to enhance animal care and improve food safety while promoting sustainable farming practices. With a commitment to animal health and welfare, the company partners with veterinarians, farmers, and pet owners to deliver effective health management solutions. Read More
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst performers in the pharmaceuticals industry.
Shares of animal health company Elanco (NYSE:ELAN)
jumped 4.4% in the morning session after the company announced it will be joining the S&P MidCap 400 index.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 7.7%. This drop is a noticeable divergence from the S&P 500’s 5.5% return.
Animal health company Elanco (NYSE:ELAN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was better than expected at $1.10 billion at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 29.5% above analysts’ consensus estimates.
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was better than expected at $1.1 billion at the midpoint, 0.9% above analysts’ estimates. Its non-GAAP profit of $0.26 per share was 29.5% above analysts’ consensus estimates.
Shares of animal health company Elanco (NYSE:ELAN)
jumped 3% in the pre-market session after the company received approval from the European Commission for its canine dermatitis treatment, Zenrelia.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.
